Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Bayer, RIKEN Innovation Tie Up on Drug Discovery
October 9, 2019
- AbbVie Japan Set to Join Oncology Fray with CLL Drug, Accelerating FIH Trial Entry
October 9, 2019
- Toray Launches Recall of Careload for Possible Placebo Mix-Up
October 9, 2019
- Gilead Files JAK Inhibitor Filgotinib in Japan
October 9, 2019
- Yakult to Promote Servier’s Anticancer Agent Liposomal Irinotecan in Japan
October 9, 2019
- Wholesalers Working Out Systems to Comply with Promotion Guidelines, Show Mixed Approaches to External Oversight
October 8, 2019
- Sanofi to Shed 200 Jobs in Japan
October 8, 2019
- Chris Hartz to Helm Amicus Japan
October 8, 2019
- Japan Ethical Drug Sales Up 3.0% in August: Crecon
October 8, 2019
- Keytruda Filed for Gastric Cancer in Japan
October 7, 2019
- Keytruda Remains Japan’s Top-Selling Drug in September: Encise
October 7, 2019
- Shionogi, M3 Establish New JV to Provide Disease Solutions by Integrating Physical and Digital Assets
October 7, 2019
- Trader Mitsui’s Iwai Picked for Top Job at Fuji Pharma
October 7, 2019
- All 11 Manufacturers Pull Ranitidine from Shelves, “Class I” Recalls for 9 Firms
October 4, 2019
- Japan IP High Court Favors Chugai in Hemlibra Patent Suit
October 4, 2019
- Novel Antibiotic Cefiderocol Meets Primary Endpoint in Global PIII: Shionogi
October 4, 2019
- Kissei to Leverage Its Track Record with EPO to Promote Nesp Biosimilar: President
October 4, 2019
- Novo Nordisk Poised to Cash in on New GLP-1 Agents to Hit 100 Billion Yen Japan Sales
October 3, 2019
- SymBio Bags Global Rights to Antiviral Brincidofovir from US Biotech, Aiming to Become Hematology Specialty Pharma
October 3, 2019
- Astellas to Make US$13 Million Investment in Boston Area to Support Startups
October 3, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…